secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001213900-26-053916
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt
--------------------------------------------------------------------------------

- Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.
- Entire unpaid principal balance of $3.8M now due 91 days after senior debt fully paid and loan agreement terminated.
- Prior maturity triggers from capital raises, debt/equity issuance, or royalty monetization eliminated.
- New voluntary conversion feature allows parent to convert principal into shares at $0.90 per share, subject to subsidiary approval.
- Note subordinated to Avenue Venture Opportunities Fund's senior debt; cash prepayment prohibited before new maturity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/0001213900-26-053916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/ea0289731-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-053916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer